Oncology

The novel antibody-drug conjugate is the first to demonstrate overall survival benefits in patients who were already treated with therapy.

The therapy had a clinically meaningful response in patients with relapsed or refractory (R/R) follicular lymphoma and R/R mantle cell lymphoma.

Study examines association between breast cancer survival and neighborhood-level measures such as socioeconomic status.

Immature data suggest enzalutamide combination improves overall survival in patients with high-risk biochemical recurrence.

The system is considered effective at identifying residual breast cancer following surgical resection.

The treatment showed significant improvement in patients in patients who require frequent blood transfusions and are at risk of infection.

Relative risk of cancer-related death differed according to age of diagnosis.

Up to 80% of patients with hepatocellular carcinoma will experience disease recurrence.

Prediagnostic weight loss could be an important marker for colorectal cancer diagnosis.

Six weeks after infusion of GD2-CART01, 9 of 27 patients (33%) with relapsed or refractory high-risk neuroblastoma had a complete response or maintained a complete response.

Limitations on a woman’s options when pregnant and diagnosed with cancer can directly impact her ability to save her own life and preserve her fertility for future pregnancies.

Choosing the best biosimilar based on reimbursement can be challenging.

Lowering blood pressure could be dangerous for people with normal blood pressure.

Infusion reactions in the switching group did not occur with switching, but rather only with reference trastuzumab administration.

Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

The gene-editing technology has been used successfully in a pediatric patient with T-cell ALL.

As psychedelic medicine comes further into cancer care, pharmacists will be an important part of the interdisciplinary team in screening and evaluating patients for suitability for psychedelic medicine.

A panel of experts discuss how to define traditional vs nontraditional careers in oncology pharmacy.

In a phase 3 trial, the risk of disease progression, relapse, or death was reduced by 27% with polatuzumab vedotin-piiq plus R-CHP compared with R-CHOP in adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma.

Mosunetuzumab-axgb may be better tolerated by older adults with relapsed or refractory follicular lymphoma and patients with poor performance status.

Omidubicel-onlv therapy aims to quicken the recovery of neutrophils and reduce the risk of infection in patients with cancer.

Durvalumab lowered the risk of death by 32% in patients with non-small cell lung cancer compared to chemotherapy alone.

Substantial strides have been made in the management of Ph+ ALL.

The treatment from Keytruda and Merck shows a clinical response of 89% for individuals with unresectable metastatic desmoplastic melanoma.

Multicancer early detection test could detect cancer with an AUC of 0.94 for all cancer types and stages.

According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.

Major pathologic response had a high association with increased recurrence-free survival rates.